{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:29:00Z","timestamp":1740115740866,"version":"3.37.3"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Amiodarone hydrochloride is an antiarrhythmic drug used to treat supraventricular tachycardia. However, there are currently no commercial pediatric forms available to treat young patients. Various oral formulations were previously reported in the literature, but the concentration was lower than the doses prescribed in clinical practice (a loading dose of 500 mg\/m2\/day for 7-10 days followed by a maintenance dose of 250 mg\/m2\/day). The objective of this study was to develop an oral liquid formulation of amiodarone hydrochloride at an optimal concentration for use in children and to evaluate its physicochemical and microbiological stability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>No commercial suspension vehicle was used, allowing the choice of excipients. Compounding was performed using hydroxypropylmethylcellulose as thickener, potassium sorbate preservative, citric acid\/sodium citrate buffer, sodium saccharin as sweetener, and a strawberry flavoring agent. A concentration of 40 mg\/mL was selected based on a 5-year compilation of prescribed doses. Analyses performed were the following: visual and microscopic inspection, testing for antimicrobial preservation, osmolality and pH measurements, quantification of amiodarone hydrochloride by a stability-indicating liquid chromatography method, and a microbiological count.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At least 95% of the initial amiodarone hydrochloride remained stable during the 60-day study period under refrigeration. All other tested parameters remained stable at 5 \u00b0C. A targeted log reduction of the microorganism inoculum by day 14 and no microbial growth by day 28 were demonstrated in the test for antimicrobial preservation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The stability of 40 mg\/mL amiodarone hydrochloride oral suspension was maintained under refrigeration for 60 days before opening bottles and for 1 month after opening bottles.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae299","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T13:17:44Z","timestamp":1729084664000},"page":"e274-e284","source":"Crossref","is-referenced-by-count":0,"title":["Physicochemical and microbiological stability of 40 mg\/mL amiodarone hydrochloride oral suspension"],"prefix":"10.1093","volume":"82","author":[{"given":"Marine","family":"Cavelier","sequence":"first","affiliation":[{"name":"Department of Pharmacy, CHU Rouen, Normandie University , UNIROUEN, EA7510 ESCAPE, Rouen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Gond\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU Rouen, Normandie University , Rouen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Parasitology-Mycology, CHU Rouen, Normandie University , Rouen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Lamoureux","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, CHU Rouen , Rouen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, CHU Rouen , Rouen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Varin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, CHU Rouen, Normandie University , Rouen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Hervou\u00ebt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU Rouen , Rouen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"issue":"6","key":"2025022017452964800_CIT0001","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ipej.2019.09.004","article-title":"Neonatal supraventricular tachycardia","volume":"19","author":"Srinivasan","year":"2019","journal-title":"Indian Pacing Electrophysiol J"},{"issue":"6","key":"2025022017452964800_CIT0002","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.earlhumdev.2015.04.001","article-title":"Treatment of supraventricular tachycardia in infants: analysis of a large multicenter database","volume":"91","author":"Chu","year":"2015","journal-title":"Early Hum Dev"},{"issue":"8","key":"2025022017452964800_CIT0003","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2174\/138161208784007761","article-title":"Supraventricular tachycardia in infants: epidemiology and clinical management","volume":"14","author":"Calabr\u00f2","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"4","key":"2025022017452964800_CIT0004","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/j.1552-4604.1984.tb01822.x","article-title":"A classification of antiarrhythmic actions reassessed after a decade of new drugs","volume":"24","author":"Vaughan Williams","year":"1984","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2025022017452964800_CIT0005","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00008480-200304000-00010","article-title":"Amiodarone-an \u201cold\u201d drug with new recommendations","volume":"15","author":"McKee","year":"2003","journal-title":"Curr Opin Pediatr"},{"issue":"16","key":"2025022017452964800_CIT0006","doi-asserted-by":"publisher","first-page":"45F","DOI":"10.1016\/0002-9149(93)90962-c","article-title":"Pharmacokinetics of amiodarone: implications for drug therapy","volume":"72","author":"Roden","year":"1993","journal-title":"Am J Cardiol"},{"key":"2025022017452964800_CIT0007","doi-asserted-by":"publisher","DOI":"10.5772\/60418","article-title":"A Review on amiodarone as an antiarrhythmic drug","author":"Mehraein","year":"2015","journal-title":"IntechOpen"},{"issue":"19","key":"2025022017452964800_CIT0008","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1136\/hrt.2008.152652","article-title":"Amiodarone: an effective antiarrhythmic drug with unusual side effects","volume":"96","author":"van Erven","year":"2010","journal-title":"Heart"},{"issue":"5","key":"2025022017452964800_CIT0009","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/PEC.0b013e3181ddd2d6","article-title":"Amiodarone for the emergency care of children","volume":"26","author":"Lane","year":"2010","journal-title":"Pediatr Emerg Care"},{"author":"DrugBank Online","key":"2025022017452964800_CIT0010"},{"issue":"6","key":"2025022017452964800_CIT0011","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0735-1097(83)80338-6","article-title":"Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias","volume":"2","author":"Greene","year":"1983","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2025022017452964800_CIT0012","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/a:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"key":"2025022017452964800_CIT0013","doi-asserted-by":"publisher","first-page":"105437","DOI":"10.1016\/j.ejps.2020.105437","article-title":"A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children","volume":"152","author":"Bhatt-Mehta","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2025022017452964800_CIT0014","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1542\/peds.72.3.356","article-title":"Benzyl alcohol: toxic agent in neonatal units","volume":"72","year":"1983","journal-title":"Pediatrics"},{"key":"2025022017452964800_CIT0015"},{"issue":"7-8","key":"2025022017452964800_CIT0016","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/106002809703100707","article-title":"Stability of amiodarone in an oral suspension stored under refrigeration and at room temperature","volume":"31","author":"Nahata","year":"1997","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2025022017452964800_CIT0017","first-page":"420","article-title":"Stability assessment of 10 active pharmaceutical ingredients compounded in SyrSpend SF","volume":"19","author":"Geiger","year":"2015","journal-title":"Int J Pharm Compd"},{"issue":"5","key":"2025022017452964800_CIT0018","first-page":"389","article-title":"Formulation and accelerated stability studies for an extemporaneous suspension of amiodarone hydrochloride","volume":"7","author":"Alexander","year":"2003","journal-title":"Int J Pharm Compd"},{"issue":"suppl 1","key":"2025022017452964800_CIT0019","doi-asserted-by":"publisher","first-page":"A208","DOI":"10.1136\/ejhpharm-2016-000875.472","article-title":"PP-033 stability study of 20 mg\/ml paediatric amiodarone oral suspension in Syrspend","volume":"23","author":"Quilliec","year":"2016","journal-title":"Eur J Hosp Pharm"},{"year":"1995","author":"European Medicines Agency","key":"2025022017452964800_CIT0020"},{"issue":"3","key":"2025022017452964800_CIT0021","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jpba.2004.07.027","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal\u2014part I","volume":"36","author":"Hubert","year":"2004","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"2025022017452964800_CIT0022","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jpba.2007.06.013","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal \u2013 part II","volume":"45","author":"Hubert","year":"2007","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"2025022017452964800_CIT0023","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jpba.2007.06.032","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal\u2013part III","volume":"45","author":"Hubert","year":"2007","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"2025022017452964800_CIT0024","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jpba.2008.07.018","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal: part IV. Examples of application","volume":"48","author":"Hubert","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"2025022017452964800_CIT0025","article-title":"Part 1: liquid preparations","volume-title":"Methodological Guidelines for Stability Studies of Hospital Pharmaceutical Preparations","author":"Brossard","year":"2013"},{"year":"2018","author":"European Medicines Agency","key":"2025022017452964800_CIT0026"},{"issue":"2","key":"2025022017452964800_CIT0027","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1208\/s12249-016-0584-1","article-title":"European Paediatric Formulation Initiative (EuPFI) \u2013 formulating ideas for better medicines for children","volume":"18","author":"Salunke","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"2025022017452964800_CIT0028","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/pharmaceutics11100518","article-title":"Innovations in pediatric drug formulations and administration technologies for low resource settings","volume":"11","author":"Gerrard","year":"2019","journal-title":"Pharmaceutics"},{"issue":"10","key":"2025022017452964800_CIT0029","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1111\/bcp.15293","article-title":"From paediatric formulations development to access: advances made and remaining challenges","volume":"88","author":"Litalien","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2025022017452964800_CIT0030","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/pharmaceutics15041306","article-title":"Stability of oral liquid dosage forms in pediatric cardiology: a prerequisite for patient\u2019s safety\u2014a narrative review","volume":"15","author":"J\u00eetc\u0103","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"2025022017452964800_CIT0031","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/children9040488","article-title":"Formulation challenges and strategies to develop pediatric dosage forms","volume":"9","author":"Malkawi","year":"2022","journal-title":"Children"},{"issue":"19","key":"2025022017452964800_CIT0032","doi-asserted-by":"publisher","first-page":"7118","DOI":"10.3390\/ijms21197118","article-title":"Paediatric formulation: design and development","volume":"21","author":"Lopalco","year":"2020","journal-title":"Int J Mol Sci"},{"year":"2006","author":"European Medicines Agency","key":"2025022017452964800_CIT0033"},{"key":"2025022017452964800_CIT0034","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2147\/IJGM.S280330","article-title":"Safety and biopharmaceutical challenges of excipients in off-label pediatric formulations","volume":"13","author":"Belayneh","year":"2020","journal-title":"Int J Gen Med"},{"issue":"3","key":"2025022017452964800_CIT0035","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030387","article-title":"Excipients in the paediatric population: a review","volume":"13","author":"Rouaz","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"2025022017452964800_CIT0036","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1021\/la962060h","article-title":"Liquid crystals and colloids in water\u2212amiodarone systems","volume":"14","author":"Bouligand","year":"1998","journal-title":"Langmuir"},{"issue":"2","key":"2025022017452964800_CIT0037","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcis.2009.10.071","article-title":"Colloidal properties of amiodarone in water at low concentration","volume":"342","author":"Benedini","year":"2010","journal-title":"J Colloid Interface Sci"},{"issue":"8","key":"2025022017452964800_CIT0038","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.clinthera.2013.06.007","article-title":"The bad taste of medicines: overview of basic research on bitter taste","volume":"35","author":"Mennella","year":"2013","journal-title":"Clin Ther"},{"key":"2025022017452964800_CIT0039","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.addr.2014.02.012","article-title":"Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients","volume":"73","author":"Walsh","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"volume-title":"Handbook of Pharmaceutical Excipients","year":"2009","author":"Rowe","key":"2025022017452964800_CIT0040"},{"issue":"2","key":"2025022017452964800_CIT0041","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5863\/1551-6776-26.2.172","article-title":"Osmolality of commonly used oral medications in the neonatal intensive care unit","volume":"26","author":"Shah","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"2025022017452964800_CIT0042","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000513169","article-title":"The risk of necrotizing enterocolitis following the administration of hyperosmolar enteral medications to extremely preterm infants","volume":"118","author":"Latheef","year":"2021","journal-title":"Neonatology"},{"issue":"2","key":"2025022017452964800_CIT0043","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/ejhpharm-2015-000860","article-title":"Ready-to-use parenteral amiodarone: a feasibility study towards a long-term stable product formulation","volume":"24","author":"Jacobs","year":"2017","journal-title":"Eur J Hosp Pharm"},{"key":"2025022017452964800_CIT0044","doi-asserted-by":"publisher","DOI":"10.1590\/s2175-97902019000418162","article-title":"Stability-indicating HPLC method for determination of amiodarone hydrochloride and its impurities in tablets: a detailed forced degradation study","volume":"56","author":"Coelho","year":"2020","journal-title":"Brazilian Journal of Pharmaceutical Sciences"},{"key":"2025022017452964800_CIT0045","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharma.2012.02.001","article-title":"Stability study of amiodarone hydrochloride in capsules for paediatric patients using a high-performance liquid chromatography method. Annales Pharmaceutiques Fran\u00e7aises","author":"Rughoo","year":"2012"},{"issue":"4","key":"2025022017452964800_CIT0046","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/87551225211015566","article-title":"Beyond-use dates assignment for pharmaceutical preparations: example of low-dose amiodarone capsules","volume":"37","author":"Brun","year":"2021","journal-title":"J Pharm Technol"},{"key":"2025022017452964800_CIT0047","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1365\/s10337-005-0554-3","article-title":"Validation of a stability indicating LC method for amiodarone HCL and related substances. Chroma","author":"Khan","year":"2005"},{"issue":"1","key":"2025022017452964800_CIT0048","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1081\/JLC-120027088","article-title":"Validation of a stability-indicating HPLC method for the determination of amiodarone HCl and its related substances in amiodarone HCl injection","volume":"27","author":"Christopherson","year":"2004","journal-title":"Journal of Liquid Chromatography & Related Technologies"},{"key":"2025022017452964800_CIT0049","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10812-019-00761-0","article-title":"Application of spectral methods to study the stability of amiodarone hydrochloride micellar solutions","volume":"85","author":"Leontiev","year":"2019","journal-title":"J Appl Spectrosc"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae299\/61182645\/zxae299.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/5\/e274\/61182645\/zxae299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/5\/e274\/61182645\/zxae299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:45:36Z","timestamp":1740073536000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/5\/e274\/7823742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,16]]},"published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae299","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2025,3,1]]},"published":{"date-parts":[[2024,10,16]]}}}